论文部分内容阅读
目的探讨抑癌基因P53蛋白在上皮性卵巢癌中的表达及与预后的关系,建立有效的判断疾病进展及预后的指标。方法应用免疫组织化学方法检测72例上皮性卵巢癌患者P53蛋白的表达,研究其与临床分期、病理类型、组织分化及预后的相关性研究。结果上皮性卵巢癌中P53蛋白有一定的表达缺失,在G1、G2级组织表达率显著低于G3;不同的临床分期中,Ⅰ、Ⅱ期阳性表达显著低于Ⅲ、Ⅳ期;在浆液性和粘液性两种类型无明显差异。P53(-)和P53(+)患者化疗的5年生存率分别为60.71%和27.27%,差异有统计学意义(P<0.05)。结论P53蛋白表达与肿瘤细胞的分期分化程度有关,与肿瘤组织学类型无关。P53蛋白表达可作为卵巢癌预后和化疗耐药的一个指标。
Objective To investigate the expression of tumor suppressor gene P53 in epithelial ovarian cancer and its relationship with prognosis and to establish an effective index to judge the disease progression and prognosis. Methods The expression of P53 protein in 72 patients with epithelial ovarian cancer was detected by immunohistochemistry. The relationship between P53 protein and clinical stage, pathological type, histological differentiation and prognosis was studied. Results The expression of P53 protein was undetectable in epithelial ovarian cancer, and the expression of P53 in G1 and G2 was significantly lower than that in G3. In different clinical stages, the positive expression in stage Ⅰ and Ⅱ was significantly lower than that in stage Ⅲ and Ⅳ. There was no significant difference between the two types of mucus. The 5-year survival rates of patients with P53 (-) and P53 (+) chemotherapy were 60.71% and 27.27%, respectively, with significant difference (P <0.05). Conclusion The expression of P53 protein is related to the degree of staging of tumor cells, but not to the histological type of tumor. P53 protein expression can be used as an indicator of ovarian cancer prognosis and chemoresistance.